Search Results
T cells with native and chimeric receptors against multiple tumor targets for acute myeloid leukemia
Adoptive T cell therapies for acute myeloid leukemia face numerous hurdles such as limited target antigens, immunosuppressive tumor environment as well as the loss of efficacy due to downregulation of the targeted antigen. The goal of our project is to address some of these challenges with a single T cell product targeting multiple tumor associated antigens that have limited expression on healthy tissues via a novel combination of native T cell receptor and gene engineered CAR targeting.
Statement on the Death of Supreme Court Justice and Trailblazer Ruth Bader Ginsburg
Photo by Nikki Khan/The Washington Post via Getty Images
Here at The Leukemia & Lymphoma Society (LLS), we are devastated to learn of the passing of Associate Justice Ruth Bader Ginsburg from complications of metastatic pancreatic cancer. As the global leader in the fight against blood cancer, we stand with the cancer community – and all Americans – in mourning this trailblazer whose contributions to public health and equality will be felt by generations to come.
Improving CAR T-cell Therapy Efficacy in Acute Lymphoblastic Leukemia by Optimizing Design and Placement
Pediatric acute lymphoblastic leukemia (ALL) that is resistant to standard therapy is a challenge that has been partially overcome by T-cell therapy, yet relapse still occurs in up to 50%. We are conducting two clinical trials that test a next-generation T-cell therapy and the first incorporation of T-cell therapy into initial therapy. These trials will inform future development and the optimal place for this therapy with the goal of improving cure rates for children with very high risk ALL.Meet an LLS Advocacy Volunteer: Amanda Steffy
Amanda Steffy of Pasadena, Calif. is one of The Leukemia & Lymphoma Society’s most passionate policy advocates. She frequently travels to Washington, D.C. to speak with lawmakers about the importance of high-quality, affordable healthcare for cancer patients. In California, where she works as an instrument systems engineer for NASA JPL, she recruits and teaches others to do the same.
This May, Steffy joins LLS for its first-ever virtual advocacy event. In this interview, Steffy explains how she first became involved in advocacy and why she’s so passionate about the work.
We Dare to Dream so Their Dreams Come True
Did you know that blood cancer is the most common cancer diagnosis for children, accounting for 40% of pediatric cancer cases? In fact, nearly 55,000 children and adolescents in the United States currently have blood cancer or are in remission from blood cancer.
Ponatinib
Ponatinib is FDA approved for the treatment of adult patients with:
Nilotinib
Tasigna® is FDA approved for the treatment of
Highlights from ASH 2021
The American Society of Hematology (ASH) annual meeting is the premier scientific forum on blood cancers. More than 5,000 potentially game-changing research abstracts were presented at this year’s meeting. Every year, I come away with a strengthened sense of hope about new treatments on the horizon and renewed pride in The Leukemia & Lymphoma Society’s (LLS) role in supporting so many of them.
Young Advocate, Big Goals: Charlotte’s Story
Imagine going to the doctor for a cold only to learn you actually have leukemia. That’s how Charlotte's experience with blood cancer began in 2018.
“The doctor diagnosed it as strep throat,” Charlotte remembers. When the antibiotics didn’t work, she “went to another doctor who diagnosed it as something else.”
IRONMAN World Championships: 5-Star Team Races for Cancer Cures
After months of rigorous training, all five LLS Team In Training teammates finished at the 2017 IRONMAN World Championships in Kona, Hawaii on October 7. The team came together from across the U.S. and Canada to compete in the 140.6 mile iconic triathlon – raising an incredible $435,000 and counting, for blood cancer cures.After months of rigorous training, all five LLS Team In Training teammates finished at the 2017 IRONMAN World Championships in Kona, Hawaii on October 7. The team came together from across the U.S.
Companies Take on Blood Cancer
Corporations usually have enough on their plate, just taking care of business, but at least one has found a creative way to also help generate millions of dollars to fund blood cancer research, education and patient services.
Pluripotent Stem Cell-derived CAR-T and CAR-NK Cells for Immunotherapy of Leukemia and Lymphoma
Cytotoxic cells of the immune system, including T and NK cells, can be targeted to seek out and destroy leukemia, lymphoma and myeloma cells by engineering them to express chimeric antigen receptors (CARs) which empower the cell to home to and kill the cancer cells. Typically, such CAR-T and CAR-NK cells are generated from a patient's own blood, but sometimes heavy pre-treatment with chemotherapy leaves inadequate supplies of T and NK cells.
Ushering In a New Era of Pediatric Blood Cancer Treatment and Care
We caught up with Gwen Nichols, MD, Chief Medical Officer at The Leukemia & Lymphoma Society (LLS), to share the progress we’re making to bring cures and better care to children with blood cancer through The LLS Children’s Initiative.
Tell us about The LLS Children’s Initiative and why it’s so important to you and LLS.
High Hopes: How a Rising Star Basketball Player’s Story is Bringing Light to the Darkness of Cancer
Each year, from September to November, thousands of illuminated lanterns light up the sky across the country as part of The Leukemia & Lymphoma Society’s Light The Night fundraising campaign – all to end cancer. For one rising star basketball player and Light The Night Honored Hero, Maurice Smith, taking steps to end cancer gave him, and so many others, high hopes for a brighter future.
Blood Cancer Research Poised for Another ‘Banner Year’ in 2024
More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.
6-Thioguanine
6-Thioguanine is FDA approved for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
Progress and Challenges in Treating the Blood Cancers: #ASH19
It’s that time of year again, when more than 30,000 scientists specializing in blood cancers and other blood disorders, oncologists and hematologists, pharmaceutical and biotechnology company representatives, and cancer patient advocacy organizations gather in one place to learn about the latest progress in treatments and share new ideas.
This year, we’re in sunny Orlando for the 61st ASH (American Society of Hematology) Annual meeting and Exposition.